Celltrion Healthcare’s Truxima (rituximab) has been listed on Australia’s Pharmaceutical Benefits Schedule from 1 January this year. But unlike Sandoz’ Riximyo rival to Roche’s MabThera reference biologic, Truxima is only listed for oncology use under the PBS’ Efficient Funding of Chemotherapy, or EFC, program that provides funding for chemotherapy drugs that are administered through infusion or injection at public or private hospitals.
Prescriptions for all rituximab brands, including Truxima, Riximyo and MabThera, under the EFC program are subject to streamlined authority. This...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?